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1. Introduction
Generalised anxiety disorder (GAD) is a common disorder with 
a lifetime prevalence of 6.1% and a 1-year prevalence of 2.9% in 
one large study.[1] It occurs most commonly in the 45 - 55-year 
age group with women twice as likely as men to have GAD.[1] 
Although symptoms typically wax and wane in intensity over time, 
the disorder is characterised by chronicity and is associated with 
high levels of psychiatric comorbidity (e.g. major depression and 
other anxiety disorders), physical comorbidity (e.g. gastrointestinal, 
respiratory, and thyroid disorders) and reduced quality of life.[2] 
There have been important advances in the nosology and treatment 
of this disorder. In particular, there is increasing evidence that 
patients with GAD and mixed anxiety-depression frequently 
present in primary care settings,[3] and the Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition[4] provides fairly 
user-friendly criteria for the diagnosis of GAD. Table 1 lists the 
diagnositic criteria.[5]
A few simple points can perhaps be made to help conceptualise 
GAD. GAD can perhaps be viewed as a ‘tension disorder’. This is 
a useful term in so far as it crosses the boundary between psychic 
symptoms (worries, feeling ‘keyed up’, irritability) and somatic 
complaints (muscle tension, restlessness, insomnia). While GAD 
patients may not present with ‘worries’, they often describe themselves 
as ‘worriers’ – worry may represent an avoidance behaviour that is 
used to diminish tension (analogous to the way that agoraphobia may 
develop after panic attacks).
The algorithm presented here (Fig. 1)[6] provides a step-by-step 
approach to the pharmacotherapy of GAD, based on our reading of the 
research literature. It is important to mention at the outset, however, 
that psychotherapy approaches may be a first-line intervention in 
some GAD patients and should be considered in all patients with this 
disorder. In addition, psycho-education is of the utmost importance, 
particularly in the initial stages of treatment, and should address the 
direct effects of anxiety on the life of the patient, as well as possible 
effects on family members.
2. Diagnosis and clinical characteristics
GAD is characterised by chronic, excessive, difficult-to-control 
worry and a range of somatic symptoms. Making the correct 
diagnosis is essential. Given that GAD often presents with somatic 
symptoms and comorbid psychiatric disorders, the diagnosis is 
frequently overlooked. It is therefore important to establish (i) 
that persistent and excessive anxiety and worry about commonly 
occurring events and activities – on more days than not for at least 
6 months – is present; (ii) that difficulty in controlling the worries is 
concomitant with physical and psychic symptoms; (iii) that the focus 
of anxiety and worry is not part of another Axis I disorder or due to 
the direct physiological effects of a substance or a general medical 
condition; and (iv) that clinically significant distress or functional 
impairment is evident.[4] 
3. Assessment
Particular attention should be paid to the evaluation of symptoms that 
are chosen as targets for pharmacotherapy and to symptoms that may 
point to the presence of other psychiatric disorders. It is also useful 
to determine the severity of GAD symptoms using a scale such as the 
Hamilton Anxiety Scale. There are a number of other screening and 
assessment scales that can be used, including the 7-item GAD scale[7] 
for screening for GAD and assessing severity, the Generalized Anxiety 
Disorder Severity Scale (DGSS) which consists of 8 DSM-IV-TR GAD 
symptoms for the assessment of symptom frequency and intensity[8] 
and the Daily Assessment of Symptoms-Anxiety (DAS-A) to assess 
for symptom improvement.[9] It is possible that the situation in GAD 
mirrors that in depression, where less severe forms of the disorder 
respond equally well to pharmacotherapy and to psychotherapy.
It is also necessary to rule out the presence of comorbid psychiatric 
and medical disorders. This includes a thorough physical examination, 
appropriate laboratory investigation (with attention to thyroid and 
glucose function), and assessment of current use of prescription or 
over-the-counter medications. Mood disorders, such as depression and 
dysthymia, other anxiety disorders, and alcohol and other substance 
use disorders are common in patients with GAD. In addition, attention 
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Table 1. Criteria for generalised anxiety disorder[5]*
A.  Excessive anxiety and worry (apprehensive expectation), occurring 
more days than not for at least six months, about a number of events or 
activities (such as work or school performance)
B. The person finds it difficult to control the worry
C.  The anxiety and worry are associated with three (or more) of the 
following 6 symptoms (with at least some symptoms present for more 
days than not for the past 6 months:
1. Restlessness or feeling keyed up or on edge
2. Being easily fatigued
3. Difficulty concentrating or mind going blank
4. Irritability
5. Muscle tension
6.  Sleep disturbance (difficulty falling or staying asleep, or restless 
unsatisfying sleep)
D. † The focus of the anxiety and worry is not confined to features of an 
Axis I disorder
E.  The anxiety, worry, or physical symptoms cause clinically significant 
distress or impairment in social, occupational, or other important areas 
of functioning
F.  The disturbance is not due to the direct physiological effects of a 
substance (e.g. a drug of abuse, a medication) or a general medical 
condition (e.g. hyperthyroidism) and does not occur exclusively during 
a mood disorder, a psychotic disorder, or a pervasive developmental 
disorder
* Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision (Copyright © 2000). American Psychiatric Association. For educational 
purposes only.
† In the DSM-V[4] this criterion has been changed to: ‘The disturbance is not better explained by 
another mental disorder
GUIDELINE
August 2013  Vol. 19  No. 3    -  SAJP    176
should be paid to the possibility of comorbid 
somatisation disorder. Children with pervasive 
anxiety probably deserve specialist evaluation 
before a diagnosis of GAD is made.
4. Treatment
4.1 Treatment goals
The goal of treatment of GAD is reduction 
and ideally elimination of symptoms or 
worry and anxiety, and restoration of normal 
functioning.[10]
4.2 General aspects of treatment
The initial treatment of GAD can arguably be 
either medication or psychotherapy as both 
approaches are efficacious. Several factors may 
complicate GAD, thus impacting on decisions 
about the choice of pharmacotherapy and other 
interventions. The most important factors, 
along with their treatment implications, are 
listed below. In addition, prior response to 
treatment and patient preference are important 
considerations. 
4.2.1 Geriatric patients
Research indicates that GAD in the elderly 
is not uncommon and is often accompanied 
by depression.[11] Given the possibility of 
accumulation of the drug and consequent 
adverse effects such as motor vehicle 
accidents, falls and fractures, benzodiazepines 
(particularly in high doses or those with 
long half-lives) should be prescribed only 
with great caution in this population. In 
addition, dosages of many other psychotropic 
medications require adjustment in the elderly.
4.2.2 Alcohol and/or substance use
When the diagnosis of GAD predates the 
onset of substance abuse, treatment may be 
initiated relatively soon after abstinence. 
However, when symptoms of anxiety have 
their onset during substance abuse or 
withdrawal, it is likely that a longer period of 
abstinence is indicated prior to re-evaluation 
of the need for treatment. In addition, given 
the risk of dependence, benzodiazepines 
should be used with caution in patients with a 
history of substance abuse.[12]
4.2.3 Other comorbid disorders
As noted earlier, there is a high rate of 
comorbidity among GAD, other anxiety 
disorders and mood disorders. GAD will 
often respond to the antidepressants that 
are used as first-line medication in these 
disorders, and these agents should therefore be 
considered initially. Similarly, in patients with 
chronic anxiety and comorbid personality 
disorder (e.g. borderline personality disorder), 
antidepressants may be a consideration.
4.2.4 Pregnancy, lactation, menopause
Pharmacotherapy should ideally be avoided 
during pregnancy and lactation. Nevertheless, 
where clinical considerations outweigh 
the risk of medication, such intervention 
should be considered after consultation 
with a specialist. In particular, there is a 
growing literature pointing toward relative 
safety of fluoxetine in pregnancy.[13] Certain 
benzodiazepines (e.g. chlordiazepoxide) 
may be safer, while others (e.g. alprazolam) 
should be avoided during pregnancy and 
lactation; the lowest effective dose should be 
prescribed for the shortest possible duration, 
and high peak concentrations should be 
avoided by dividing the daily dosage into two 
or three doses.[14] Anxiety symptoms may be 
exacerbated in susceptible patients during 
menopause, and hormone replacement 
therapy may be considered as an adjunct to 
standard pharmacotherapy.
4.2.5 Comorbid medical disorders and 
medications
Clinicians need to be aware of the multiple 
interactions between medications used in 
the treatment of GAD and the treatment of 
other disorders, as well as of the impact of 
the medication's adverse effects on medical 
disorders.
4.3 Pharmacological treatment
The first-line treatment of uncomplicated 
GAD is a selective serotonin reuptake 
inhibitor (SSRI) or serotonin-norepinephrine 
reuptake inhibitor (SNRI) drug. Given 
the substantial comorbidity of GAD 
with depression and other disorders for 
which antidepressants are effective, expert 
consensus favours the use of one of these 
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Fig. 1. Algorithm for pharmacotherapy of generalised anxiety disorder.[6]
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a range of other agents, including pregabalin, agomelatine, older 
antidepressants such as tricylics (TCAs), benzodiazepines, the 
azapirone buspirone, the antihistamine agent hydroxyzine, the first-
generation antipsychotic trifluoperazine and the second-generation 
antipsychotic quetiapine.[2,17] 
A recent meta-analysis and systematic review of the efficacy of 
nine drug treatments for GAD notes advantages and disadvantages of 
several of these agents.[18] For example, the TCAs (namely imipramine) 
have been shown effective in GAD in several controlled trials, but are 
currently considered a second-line option owing to their adverse event 
burden and toxicity in overdose.[19] Similarly, given concerns about their 
tolerability and side-effect profile, caution should be exercised in using 
atypical and typical antipsychotic medications as monotherapy in GAD. 
The benzodiazepines are best reserved for short-term use (2 - 4 
weeks) in the early phase of treatment of GAD with an SSRI or SNRI 
to provide some symptomatic relief until the antidepressant has 
begun to work, to treat insomnia if it is a predominant symptom, 
and to protect against occasional early worsening of anxiety seen 
with the initiation of therapy.[19] The high comorbidity of symptoms 
of depression in GAD, and the significant difficulties experienced by 
many patients during benzodiazepine withdrawal, constitute a strong 
argument against their long-term use. Benzodiazepines with longer 
half-lives or slow-release preparations may, however, be associated 
with fewer withdrawal problems. 
Buspirone, a 5-HT1A agonist, takes 2 - 4 weeks or longer to begin 
working, and appears to be experienced as less helpful in patients 
recently treated with benzodiazepines.[20] Its advantage lies in its 
benign side-effect profile, the lack of dependence, and its proven 
efficacy in GAD. Disadvantages include a lack of efficacy against the 
depressive symptoms often found in GAD, and a lack of efficacy in 
some trials. Whereas some SSRIs have been shown useful in children 
and adolescents with GAD, a controlled study of buspirone in this 
population was negative.
Although beta-blockers (e.g. propranolol) are often prescribed 
by general practitioners for anxiety symptoms, they have unproven 
efficacy in GAD. Kava extract is a herbal that showed some promise 
for the treatment of anxiety,[21] but it has not been studied rigorously 
enough in GAD, and there are safety concerns, viz. hepatotoxicity. 
4.4 Non-pharmacological treatment
Cognitive-behavioural treatment (CBT) has demonstrated efficacy 
in GAD, where the benefits are maintained at 6 months to 2 years of 
follow-up.[22] Treatment of GAD using CBT involves techniques of 
cognitive restructuring, worry exposure, and behaviour modification. 
There is currently little evidence that routinely initiating CBT together 
with medication improves outcome in GAD.
4.5 Acute treatment
The response time to a first-line SSRI (e.g. fluoxetine, citalopram, 
escitalopram, paroxetine, sertraline) or SNRI (e.g. venlafaxine, 
duloxetine) is usually between 4 and 12 weeks in GAD, although with 
adequate dosing a partial response may be evident by 4 - 6 weeks.[2,23] 
TCAs and benzodiazepines are also efficacious in the treatment of 
GAD, but are not considered first-line in view of their adverse event 
profile (see below). Buspirone is another option in the treatment of 
GAD (see below). 
The first step after drug initiation is to determine response to the 
medication. This is achieved by careful evaluation of change in 
symptoms initially targeted for treatment. These are typically excessive 
worry, various somatic symptoms, and consequent functional 
impairment. Determining the side-effects of the medication is also 
important, as these may influence compliance. Patients who are 
intolerant of a particular medication can of course be switched to 
another agent or to another class of agents. For example, within the 
SSRIs, adverse effects may not be seen when an alternative SSRI is 
used. 
When there is a poor response to medication, the first course of 
action is to optimise dose and duration of the treatment. For many of 
the antidepressants, there is a relationship between dose and response 
and also between dose and side-effects. Thus, optimal dosage is as 
close to maximum recommended doses that the patient can tolerate. 
Elderly patients generally require lower doses than younger adults. 
Particularly in the case of the TCAs, clinicians often prescribe 
suboptimal doses, rather than using doses of 150 mg or more of 
medications such as imipramine. Even in the case of the SSRIs, some 
patients may fail to respond to the standard initial starting dose, but 
do better at higher doses.
Furthermore, there is increasing awareness that some patients may 
be rapid metabolisers of antidepressant medication and, therefore, 
require significantly higher doses than usual. When patients on TCAs 
have little response and few anticholinergic side-effects on average 
doses of medication (e.g. imipramine 150 mg), it may be useful to 
further increase dosage with electrocardiogram and perhaps drug 
level monitoring. 
Although benzodiazepines are not recommended as first-line 
treatments, when used, they should be prescribed in an optimal 
fashion. In particular, it may be useful to replace short-acting 
agents with slow-release compounds or long-acting agents. All too 
frequently, patients on short-acting compounds have intermittent 
increases of anxiety before the next dose of medication is to be taken.
Buspirone treatment usually begins at 5 mg three times daily. This 
dose may be increased by 5 mg every 2 - 3 days. Therapeutic doses of 
buspirone range from 30 mg to 60 mg daily, typically given in divided 
doses. Buspirone has at least a 2 - 4-week time lag from initiation to 
clinical onset; optimum duration of a trial of treatment should thus 
be no less. 
At the end of a clinical trial of optimal dose and duration, patients 
should be thoroughly reassessed. There is growing recognition of 
the importance of residual anxiety symptoms in causing disability 
and predicting relapse, and of the consequent necessity of aiming for 
remission of symptoms as the endpoint of treatment.[24]
4.6 Maintenance treatment
When the patient has a good response to medication, it is important to 
reinforce the necessity for continuing the medication at the therapeutic 
dose despite this improvement.[25] It is recommended that therapy be 
continued for at least 1 year where there is a good response, given that the 
disorder is chronic and randomised controlled trials have demonstrated 
relapse with shorter-term maintenance. It is also important to regularly 
monitor efficacy and tolerability during long-term treatment. Indeed, 
guidelines for maintenance therapy of GAD emphasise the safety 
of modern agents, the likelihood of additional episodes of illness in 
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patients with repeated past episodes, and the theoretical possibility that 
appropriate treatment may prevent the onset of secondary disorders.
[15] Such guidelines have become increasingly conservative, favouring 
longer courses of medication. When a decision is made to discontinue 
medication, a gradual taper is recommended (arguably with an even 
slower taper in the elderly and in medically ill patients). 
4.7 Managing partial and non-responders
When GAD does not respond to a clinical trial of adequate dose and 
duration, it may be useful to reassess a number of important factors 
that may influence choice of further interventions.
4.7.1 Comorbidity
It is important to establish whether comorbid mood or other 
anxiety disorders are present. For example, comorbid dysthymia 
may not respond to buspirone alone, comorbid social anxiety 
disorder is unlikely to respond to a TCA (other than clomipramine), 
and comorbid hypochondriasis may require high doses of SSRIs. 
Excluding important comorbid psychiatric disorders is perhaps the 
most important step in the evaluation and management of refractory 
GAD.
4.7.2 Compliance
Many patients with GAD suffer from extreme anxiety and are in fact 
compliant with their medication. Nevertheless, there is perhaps a 
tendency for clinicians to overestimate patient compliance. Patients 
are particularly likely to be concerned about physical or psychological 
dependence on medication. It is well worth checking not only with the 
patient, but perhaps also with the family, whether medication is in fact 
taken as prescribed.
4.7.3 Comorbid substance use
In the presence of active alcohol or substance use, it may be necessary 
to shift the emphasis of treatment towards a substance use disorder 
as the primary diagnosis, with the anxiety as a secondary problem. 
Detoxification is typically a first step in the management of these 
patients.[26,27]
4.7.4 Comorbid personality disorders
Although antidepressants may be useful, additional interventions 
such as psychotherapy may be helpful in patients with chronic 
anxiety and comorbid personality disorder. While improvement in 
anxiety symptoms may reduce maladaptive behaviour in patients with 
comorbid personality disorder, there are other patients (e.g. those with 
borderline personality disorder) in whom the personality disorder 
itself may need to be a major target of treatment.
4.7.5 Underlying medical disorder
Patients with GAD who fail to show any noticeable response to 
treatment should be thoroughly reassessed for the possibility of an 
underlying medical condition. A range of different medical disorders 
may lead to chronic anxiety, including endocrine disorders (e.g. 
hyperthyroidism), respiratory disorders (e.g. chronic obstructive 
pulmonary disorders), cardiac disorders (e.g. congestive heart failure), 
and others. If present, such disorders naturally require specific 
intervention. Note that when using a benzodiazepine in patients 
with liver dysfunction, consider using those metabolised only by 
conjugation (e.g. lorazepam, oxazepam).
4.7.6 Pharmacokinetic issues
Drug-drug interactions may result in a subtherapeutic dose of the 
prescribed antidepressant.
4.7.7 Psychosocial issues
In some cases, a diagnosis of an adjustment disorder with 
anxious features may be more accurate than that of GAD, and a 
psychotherapeutic approach therefore indicated. This factor may 
partially explain high rates of placebo response in some clinical trials 
in GAD. In other cases of chronic anxiety, psychosocial factors may be 
enduring and therefore continuously complicate treatment of GAD 
until given independent attention.
Where there is only a partial response to an initial 12-week trial, 
it is prudent to re-evaluate the patient and to consider switching to 
another antidepressant within the same class or to a different class 
(e.g. SSRI to SNRI or agomelatine, SNRI to SSRI or agomelatine), 
or augmentation.[24] Neither augmentation nor switching strategies 
in GAD have been well researched. Augmentation offers the 
advantage of retaining any possible gains from the first agent, but 
the potential disadvantages of polypharmacy (more side-effects, 
drug interactions).[28] When insomnia is present, the use of an 
appropriate agent (e.g. non-benzodiazepine gamma-amino-butyric 
acid (GABA)-ergic hypnotics such as zolpidem, agomelatine, or 
mirtazapine) may be considered.[24] If comorbid depression is 
present, augmentation with bupropion, buspirone, or an atypical 
antipsychotic may be considered. Similarly, if there is a comorbid 
bipolar disorder, a mood stabiliser, anticonvulsant or an atypical 
antipsychotic may be considered. Augmentation with psychotherapy 
is another important consideration. 
5. Summary points
• Both pharmacotherapy and psychotherapy are efficacious first-line 
approaches for GAD.
• First-line pharmacotherapy of uncomplicated GAD comprises use 
of an SSRI or SNRI drug.
• A range of other psychotropics are useful for the treatment of GAD.
• Response time to a first-line selective SSRI (e.g. fluoxetine, 
citalopram, escitalopram, paroxetine, sertraline) or SNRI (e.g. 
venlafaxine, duloxetine) is usually between 4 and 12 weeks in GAD.
• Benzodiazepines (e.g. lorazepam, alprazolam, diazepam) are best 
reserved for short-term use (2 - 4 weeks) in the early phase of 
treatment of GAD with an SSRI or SNRI to provide symptomatic 
relief.
• Given concerns about their tolerability and side-effect profile, 
caution should be exercised in using atypical and typical 
antipsychotic medications as monotherapy in GAD. 
• CBT for GAD involves techniques of cognitive restructuring, worry 
exposure, and behaviour modification.
• Neither augmentation nor switching strategies have been well 
researched in GAD. Where there is only a partial response to an 
optimal 12-week trial, consider switching to another antidepressant 
within the same class or to a different class (e.g. SSRI to SNRI or 
agomelatine, SNRI to SSRI or agomelatine).
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